Technical Analysis for ALXO - ALX Oncology Holdings Inc.

Grade Last Price % Change Price Change
F 58.045 0.16% 0.10
ALXO closed down 9.13 percent on Monday, April 12, 2021, on 54 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical ALXO trend table...

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.66%
Multiple of Ten Bearish Other 0.66%
Wide Bands Range Expansion 0.66%
Below Lower BB Weakness 0.66%
Lower Bollinger Band Touch Weakness 0.66%
Fell Below 20 DMA Bearish -8.53%
180 Bearish Setup Bearish Swing Setup -8.53%
Multiple of Ten Bearish Other -8.53%
Wide Bands Range Expansion -8.53%
Crossed Above 20 DMA Bullish -19.19%
Older End-of-Day Signals for ALXO ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 3% about 2 hours ago
60 Minute Opening Range Breakdown about 3 hours ago
Down 2 % about 3 hours ago
Down 1% about 5 hours ago
Fell Below Previous Day's Low about 5 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Oncology Cancer Immunotherapy Acute Myeloid Leukemia Carcinoma Myelodysplastic Syndrome Epidermal Growth Factor Receptor Syndromes Solid Tumor Myelodysplastic Syndromes CD47 Treatment Of Myelodysplastic Syndrome

Is ALXO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 117.45
52 Week Low 28.01
Average Volume 269,674
200-Day Moving Average 0.00
50-Day Moving Average 75.88
20-Day Moving Average 69.94
10-Day Moving Average 69.54
Average True Range 5.76
ADX 16.48
+DI 14.98
-DI 30.37
Chandelier Exit (Long, 3 ATRs ) 65.72
Chandelier Exit (Short, 3 ATRs ) 75.01
Upper Bollinger Band 81.57
Lower Bollinger Band 58.31
Percent B (%b) -0.02
BandWidth 33.26
MACD Line -2.74
MACD Signal Line -2.20
MACD Histogram -0.535
Fundamentals Value
Market Cap 2.15 Billion
Num Shares 37.1 Million
EPS -0.74
Price-to-Earnings (P/E) Ratio -78.68
Price-to-Sales 1061.48
Price-to-Book 10.09
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 67.07
Resistance 3 (R3) 68.01 65.92 65.55
Resistance 2 (R2) 65.92 63.59 65.45 65.04
Resistance 1 (R1) 61.93 62.16 60.89 60.99 64.54
Pivot Point 59.84 59.84 59.31 59.37 59.84
Support 1 (S1) 55.85 57.51 54.81 54.91 51.36
Support 2 (S2) 53.76 56.08 53.29 50.86
Support 3 (S3) 49.77 53.76 50.35
Support 4 (S4) 48.83